Sclerotherapy versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis

Gattini, Daniela; Cifuentes, Lorena; Torres‐Robles, Romina; Gana, Juan Cristóbal

doi:10.1002/14651858.cd011573.pub2

Cited by 10 publications

(3 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35,36 As in October 2018, the FDA has approved only 12 biosimilars for various conditions, including IBD, ankylosing spondylitis, rheumatoid arthritis, certain refractory anemias, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, breast cancer and stomach cancer. 37 Three of these were infliximab biosimilars;…”

Section: Overview Of the Biosimilar Approval Process In The Usamentioning

confidence: 99%

“… 26,34 Despite the enactment of the BPCI, it took about 5 years for the FDA to approve its first biosimilar, Zarxio® (Filgrastim‐Sndz) in March 2015 35,36 . As in October 2018, the FDA has approved only 12 biosimilars for various conditions, including IBD, ankylosing spondylitis, rheumatoid arthritis, certain refractory anemias, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, breast cancer and stomach cancer 37 . Three of these were infliximab biosimilars; Inflectra® (infliximab‐dyyb) and Ixifi® (infliximab‐qbtx) (Pfizer, New York, NY, USA), and RENFLEXIS (infliximab‐abda) (Merck, Kenilworth, NJ, USA).…”

Section: Overview Of the Biosimilar Approval Process In The Usamentioning

confidence: 99%

See 1 more Smart Citation

Biosimilars in inflammatory bowel disease

Talathi

Baig

2020

J of Digest Diseases

View full text Add to dashboard Cite

The advent of biologics has changed outcomes in many chronic conditions, including inflammatory bowel disease (IBD). Biologics have been used for the induction and remission of ulcerative colitis and Crohn's disease for almost two decades and are effective in patients who used to fail conventional treatment with steroids, immunomodulators. The use of biologics in the treatment of IBD has increased over the last few years, partly due to the rise in its incidence and the use of biologics as a first‐line treatment in severe disease as well as in complicated diseases like penetrating/fistulating Crohn's disease. However, their use is associated with a significant burden to the society with respect to healthcare costs, resulting in the premature discontinuation of therapy in some patients, leading to exacerbations and complications. The introduction of biosimilars a decade ago seems to be a promising approach to reducing the costs related to therapy. Since their introduction, numerous studies conducted in adults and some in children show the efficacy of biosimilars with a similar side‐effect profile to biologics. This review discusses the history of biosimilars in the treatment of IBD, enumerates several such studies and discusses the possibility of using biosimilars in the future.

show abstract

Section: Overview Of the Biosimilar Approval Process In The Usamentioning

confidence: 99%

Section: Overview Of the Biosimilar Approval Process In The Usamentioning

confidence: 99%

Biosimilars in inflammatory bowel disease

Talathi

Baig

2020

J of Digest Diseases

View full text Add to dashboard Cite

show abstract

“…The transparent cylinder attached to the end of the gastroscope holding the bands limits the view Prophylactic endoscopic therapy is controversial. Prophylactic EIS does not offer an overall survival advantage, but EVS may be beneficial in preventing bleeding in children with large esophageal varices related to liver disease (Shneider et al 2016;Bernabeu et al 2020;Gattini et al 2020).…”

Section: Primary Prophylaxis Of Variceal Bleedingmentioning

confidence: 99%

Portal Hypertension

Stringer¹

2020

Pediatric Surgery

View full text Add to dashboard Cite

Portal hypertension (PHT) in children may be caused by a wide range of etiologies, including extrahepatic portal vein obstruction, biliary atresia, alpha-1-antitrypsin deficiency, and autoimmune hepatitis. PHT presents with acute gastrointestinal bleeding and/or splenomegaly or with symptoms and signs of chronic liver disease. Gastroesophageal varices and ascites are two main complications of PHT responsible for morbidity and mortality. This chapter describes the pathogenesis and management of PHT in children.

show abstract